

Protocol	Projected Enrollment	Accrual Period
CIT-01A (Nordic Network)(Islet Alone Protocol)-Open Randomized Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran in Islet Transplantation	36	3 years, began in June 2008
CIT-01B (Nordic Network)(Islet After Kidney Protocol)-Open Randomized Multi-Center Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran in Islet Transplantation	36	3 years, began in June 2008
CIT-02 (Miami and U of I Chicago)Strategies to Improve Long Term Islet Graft Survival	24	2 years, began in June 2008
CIT-03 (Minnesota, UCSF and Northwestern)Peritransplant Deoxyspergualin (DSG) in Islet Transplantation in Type 1 Diabetes	20	2 years, began in June 2008
CIT-04 (Edmonton and Emory)Islet Transplantation in Type 1 Diabetes with LEA29Y (Belatacept) Maintenance Therapy	20	2 years, began in October 2008
CIT-05 (Pennsylvania)B-Lymphocyte Immunotherapy in Islet Transplantation: Toward Calcineurin-Inhibitor Free Immunosuppression	12	2 years, began in June 2008
CIT-06 (8 sites)Islet Transplantation in Type 1 Diabetic Kidney Allograft Recipients	24	2 years, to begin January 2009
CIT-07 (8 sites)Islet Transplantation in Type 1 Diabetes	48	2 years, began June 2008

*Patients will be randomized between pilot studies (CIT-02, 03, 04 and 05) and the phase III CIT-07. So far 8 patients have screened eligible, 10 have failed screening and 8 are still undergoing screening.